Ligands for imaging cardiac innervation
US-12324845-B2 · Jun 10, 2025 · US
US10308591B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10308591-B2 |
| Application number | US-201815874747-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 18, 2018 |
| Priority date | Aug 10, 2006 |
| Publication date | Jun 4, 2019 |
| Grant date | Jun 4, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
This disclosure concerns the discovery of (R,R)- and (R,S)-fenoterol analogs which are highly effective at binding β2-adrenergic receptors. Exemplary chemical structures for these analogs are provided. Also provided are pharmaceutical compositions including the disclosed (R,R)-fenoterol and fenoterol analogs, and methods of using such compounds and compositions for the treatment of cardiac disorders such as congestive heart failure and pulmonary disorders such as asthma or chronic obstructive pulmonary disease.
Opening claim text (preview).
We claim: 1. A method for treating congestive heart failure in a subject, comprising: administering to the subject with the cardiovascular disorder a therapeutically effective amount of a compound having the formula 2. The method of claim 1 , wherein the compound is 3. The method of claim 1 , wherein administering a therapeutically effective amount of the compound comprises administering a pharmaceutical composition comprising the therapeutically effective amount of the compound and at least one pharmaceutically acceptable carrier. 4. The method of claim 1 , wherein administering the therapeutically effective amount of the compound to the subject increases cardiomyocyte contractility.
Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title
Drugs for disorders of the cardiovascular system · CPC title
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Antiasthmatics · CPC title
Drugs for disorders of the respiratory system · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.